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esponsibility of Xi’Abstract A simple and fast capillary electrophoresis method has been developed to determine the
amount of piroxicam loaded in a drug delivery system based on nanostructured lipid carriers (NLCs). The
entrapment efﬁciency of the nanostructured lipid carrier was estimated by measuring the concentration of
drug not entrapped in a suspension of NLC. The inﬂuence of different parameters on migration times,
peak symmetry, efﬁciency and resolution was studied; these parameters included the pH of the
electrophoretic buffer solution and the applied voltage. The piroxicam peak was obtained with a
satisfactory resolution. The separation was carried out using a running buffer composed of 50 mM
ammonium acetate and 13.75 mM ammonia at pH 9. The optimal voltage was 20 kV and the cartridge
temperature was 20 1C. The corresponding calibration curve was linear over the range of 2.7–5.4 mg/mL
of NLC suspension. The reproducibility of migration time and peak area were investigated, and the
obtained RSD% values (n¼5) were 0.99 and 2.13, respectively.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
A drug delivery system is deﬁned as a formulation or device that
allows the introduction of a therapeutic substance in the body and
improves the efﬁcacy and safety of this substance, controlling the
speed, time and place of release of the drug in the body [1,2]. Fromsity. Production and hosting by Else
3
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(M. Garrido).
an Jiaotong University.the pharmaceutical point of view, these systems show several
advantages such as stability and potential for carrying drugs of
different polarity, for increasing the drug bioavailability and improv-
ing the absorption efﬁciency [2]. Among these delivery systems, the
solid lipid nanoparticles (SLNs), which emerged in the early 1990s,
are of great interest. Basically, the SLNs are deﬁned as lipid arrays at
nanometric scale, solid at physiological temperatures and stabilized
by surfactants [3]. In addition, in recent years, a second generation of
these lipid nanoparticles have arisen as nanostructured lipid carriers
(NLCs). These carrier systems have improved the properties andvier B.V. All rights reserved.
Entrapment efﬁciency determination by capillary electrophoresis 71stability of the SLNs [1]. In the last years, owing to the great
economic and health interest in this topic, the research in this area has
signiﬁcantly increased.
The development of delivery systems involves a multidisci-
plinary approach. Analytical chemistry provides the fundamental
tools to characterize the systems, quantify the drugs loaded in the
carrier systems, perform drug release proﬁles and study the
pharmacokinetics in living organisms.
Nowadays, liquid chromatography is the principal analytical
technique used to carry out the determination of the amount of
drug loaded in this kind of systems. Normally, using this technique
requires a previous step consisting of the centrifugation of NLC
suspensions in a membrane concentrator [4–6] with the consequent
increase of potential errors arising from the sample handling.
In the last years, capillary electrophoresis (CE) has been
increasingly used as a separation analytical technique, especially
in some ﬁelds like pharmaceutical analysis, biology and modern
medicine [7–9]. This separation technique shows some advantages
such as higher speed, lower cost of analysis, and lower residues
generation [10]. Therefore, CE appears as an alternative technique
to quantify the concentration of drugs in different delivery systems.
On the other hand, non-steroidal anti-inﬂammatory drugs
(NSAIDs) are widely used in therapeutics because of their anti-
inﬂammatory and analgesic properties.
However, there are several secondary effects related to the use
of these drugs, with gastric irritation being the most common
[11,12]. Among these drugs, piroxicam is especially interesting
because of its low solubility in both organic solvents and aqueous
solutions, which could be a limitation on its passage to the
systemic circulation. Therefore, this active principle was selected
as a target analyte in the current study. The common structural
feature of NSAIDs is an acidic group, characterized by pKa values
in a range of 3–6. Thus, these compounds are mainly in the
anionic form at pH Z7. Therefore, this kind of analytes can be
determined using capillary zone electrophoresis (CZE) [13,14]
with a simple electrophoretic buffer.
The aim of this study was to evaluate the capability of capillary
electrophoresis, as an analytical technique, to determine the
concentration of piroxicam loaded in a NLC. The nanoparticles
suspension was obtained from a warm transparent microemulsion
and its entrapment efﬁciency was estimated indirectly on the base
of the amount of drug not entrapped in the NLCs (i.e., the free
drug). The inﬂuence of different electrophoretic parameters was
investigated. The proposed method has several advantages such as
low consumption of reagents, injection of small volumes of sample
and short time of analysis. The principal advantage, in comparison
with the most commonly used technique (liquid chromatography)
is that the sample does not need previous treatment and can be
directly injected in the capillary.2. Materials and methods
2.1. Apparatus
CE experiments were carried out with a Beckman Coulter
Capillary Electrophoresis Instrument MDQ (Fullerton, USA),
equipped with a diode array detector. The capillary was also from
Beckman System and before its ﬁrst use it was sequentially rinsed
with 1.0 M HCl (10 min), ultrapure water (5 min), 1.0 M NaOH
(10 min), ultrapure water (5 min), 0.1 M NaOH (5 min), ultrapurewater (3 min) and running buffer (10 min). Control and data
processing were carried out with 32 Karat software.
A magnetic stirrer with temperature control (Autoscience AM-
5250B, Tianjin, China) was used for NLCs preparation.
2.2. Chemicals and reagents
All solutions were prepared using ultrapure water (Millipore,
Bedford, MA, USA).
Ethyl oleate (Sigma Aldrich, Buenos Aires, Argentina), soya
lecithin (F.A.S. Córdoba, Argentina), polysorbate 80 (Tween 80)
(Sigma-Aldrich) and n-butanol (Baker, Chemical Center S.R.L.,
Buenos Aires, Argentina) were used for preparation of the NLCs
suspension. Piroxicam was obtained from local pharmacies.
Ammonium acetate and ammonia (Merck, Buenos Aires, Argen-
tina) were used to prepare the electrophoretic buffer solution.
2.3. Preparation of nanoparticles
The process for the elaboration of the lipid nanoparticles suspen-
sion included the following steps: preparation of the lipid phase,
preparation of the aqueous phase, formation of a microemulsion
and the subsequent obtaining of the solid nanoparticles. The lipid
phase was achieved by merging the solid (lecithin) and liquid
(ethyl oleate) lipids at 62 1C, 25% and 75% w/v, respectively. The
appropriate amount of the active principle (piroxicam) was
weighed and dissolved in the lipid phase at the same temperature
under continuous agitation. The aqueous phase was a 7.6% (m/v)
surfactant (Tween 80) solution. The microemulsion was formed by
mixing the lipidic and aqueous phases at 62 1C and with
subsequent addition of n-butanol under continuous agitation until
obtaining a unique transparent phase. Finally, nanoparticles were
formed by dispersing the hot microemulsion in cold water (at
approximately 4 1C). Also, control suspensions were prepared
following the same procedure but without piroxicam.
All the analyses were carried out on the ﬁfth day from the
preparation of the NLCs suspension. After this interval of time, the
system was stable and the turbidity was not signiﬁcant, so the
spectrometric measurements were not affected.
2.4. Electrophoretic method
Electrophoretic separation was carried out with a 65 cm 75 mm i.
d. fused-silica capillary. The piroxicam peak was satisfactory
obtained working with a buffer solution consisting of 50 mM
ammonium acetate and 13.75 mM ammonia at pH 9. This pH
value was adjusted with 1.0 M NaOH. The applied voltage was
20 kV. Injections were made in hydrodynamic mode during 5 s at
0.5 psi. The capillary was thermostatized at 20 1C.
Before each injection, the capillary was rinsed with ultrapure
water (1 min), 0.1 M NaOH (2 min), and running buffer (5 min).
The electropherograms were recorded at 220 nm.3. Results and discussion
3.1. Separation conditions
The optimization of the separation conditions was performed using
a control suspension to which suitable amounts of piroxicam were
added (i.e., control suspension of NLCsþfree piroxicam).
Table 1 Results for calculating the entrapment efﬁciency in
different piroxicam-loaded NLCs.
Amount of
piroxicam
used to
prepare the
NLCs (mg)a
Amount of
free
piroxicam
(mg)a
Difference
(mg)
Amount of piroxicam
loaded in NLCs
(mg/g)
4.32 2.62 1.70 0.11
4.86 3.11 1.75 0.11
5.40 3.35 2.05 0.13
8.10 6.20 1.90 0.12
9.50 7.50 2.00 0.13
10.80 9.08 1.72 0.11
13.50 11.40 2.10 0.13
X ¼ 0:12;RSD%¼ 8:3
aCorresponding to 1 mL of suspension.
J. Otarola et al.72A solution consisting of 50 mM ammonium acetate and
13.75 mM ammonia was selected as running buffer, taking into
account the Fillet et al. publication [15]. The pH of this solution
was tested over the range of 7.0–9.3. The peak of piroxicam was
not appreciated using pH values between 7 and 8. At pH values
around 9 the piroxicam signal was detected. Therefore, consider-
ing the separation efﬁciency, the symmetry of the peak shape and
the stability of the baseline, the pH of buffer solution was kept
at 9.0.
The effect of the applied voltage was also investigated (15–
25 kV). The results indicated that higher voltage corresponded to
shorter analysis time but to lower peak areas. So, 20 kV was
selected as the optimum separation voltage.
3.2. Figures of merit
Fig. 1 shows the electropherogram of the control suspension, and
the same suspension with the addition of 0.18 mg of piroxicam.
The peak of free piroxicam appeared with a good resolution
respect to one corresponding to the control suspension. Thus, the
calibration curve was obtained by measuring the peak areas
corresponding to different amounts of piroxicam added to the
control suspension.
The relationship between the peak areas and the corresponding
concentrations of piroxicam was linear in the range of 2.7–5.4 mg/
mL. The regression equation was A¼5904.5C10,361, where A
is the peak area and C the concentration of piroxicam in μg/mL
(R2¼0.997). The reproducibility of migration time and peak area
were investigated, and the obtained RSD% values (n¼5) were
0.99% and 2.13%, respectively.
3.3. Entrapment efﬁciency
The study of the entrapment efﬁciency involved a set of four
replicates of a suspension of piroxicam-loaded NLCs prepared
using 8.10 mg of piroxicam per millilitre of suspension. These
suspensions were injected into the capillary and the peak areas of
free piroxicam were measured. Thus, the entrapment efﬁciency
was obtained by differences between the amount of piroxicam
used to prepare the NLCs suspensions and the amount of
piroxicam non-entrapped in the NLCs, which was quantiﬁed by
CE. The average value of entrapment efﬁciency was 0.12 mg of
loaded piroxicam per g of NLCs. The results were expressed as perFig. 1 Electropherograms of control solution (black line) and control
solution with piroxicam (grey line).gram of nanoparticles, taking into account that 1 mL of NLCs
suspension corresponds to 15.8 mg of nanoparticles. The RSD%
was 1.08 (n¼3).
In order to investigate the performance of the proposed method,
a set of different suspensions with increasing amounts of drug
were prepared. Table 1 shows the obtained results.
In all cases the results were similar, even though the amounts of
piroxicam used to prepare the NLCs were quite different. This fact
would indicate that the proposed method provided reliable results.4. Conclusion
A fast, effective and reliable CE method to determine the
entrapment efﬁciency of an NLCs-based delivery system for
piroxicam was developed. The proposed method used a simple
electrophoretic buffer solution with a short time of analysis (about
10 min). It is important to note that the suspensions were injected
into the capillary without any pre-treatment. Similar methods
could be developed to determine the entrapment efﬁciency of
others carriers system, based on the proposed method. Also, with
the corresponding optimized electrophoretic conditions, other
drugs could be analyzed.
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